Medindia

X

Sagent Completes $30 Million Series A Financing Extension

Thursday, September 4, 2008 General News J E 4
Advertisement
SCHAUMBURG, Ill., Sept. 4 Sagent Pharmaceuticals, Inc., aprivately-held specialty pharmaceutical company today announced the closing ofa $30 million extension of last year's $53 million Series A financing, led byVivo Ventures. Proceeds from the financing will be used to fund near-termproduct launches, product development activities and strategic businessinitiatives.

"This additional financing round will allow us to advance additionalproducts to market and to avail ourselves of compelling, recently discoveredproduct acquisition opportunities," said Jeffrey M. Yordon, CEO, founder andchairman of the board of Sagent Pharmaceuticals. "We appreciate the continuedcommitment our investors have demonstrated to Sagent through this financing."

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialtypharmaceutical company focused on developing, manufacturing, sourcing andmarketing pharmaceutical products, with a specific emphasis on injectableproducts. Sagent has created a unique, global network of resources, comprisedof rapid development capabilities, sophisticated manufacturing and innovativedrug-delivery technologies, quickly yielding an extensive portfolio ofpharmaceutical products that fulfills the evolving needs of patients. Sagentcurrently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, pleasevisit http://www.SagentPharma.com.

About Vivo Ventures

Vivo Ventures is a life-sciences focused venture capital firm with morethan $650 million under management. Vivo Ventures is currently makinginvestments from its sixth fund of $275 million into promising biotechnologyand life science companies.

With more than 90 years of scientific and operational expertise inbiotechnology, Vivo helps its portfolio companies develop corporate strategy,arrange licensing agreements and strategic alliances, recruit key managementpersonnel and acquire new products and technology to accelerate growth. Itscurrent portfolio includes more than 60 private and public biotechnologycompanies in the areas of biopharmaceuticals, specialty pharmaceuticals andmedical devices.

SOURCE Sagent Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
China Sky One Medical Announces Successful Marketi...
S
NeuroFocus Obtains 'Core Patent' for Applying Neur...